Drug Metabolism: From Experiments to Regulatory Aspects

References

• Kaufmann R. Matrix-assisted laser desorption ionization (MALDI) mass spectrometry: A novel analytical tool in molecular biology and biotechnology. J. Biotechnol. 1995; 41: 155–175
   PubMed Web of Science ®Google Scholar
• Nguyen D. N., Becker G. W., Riggin R. M. Protein mass spectrometry: Applications to analytical biotechnology. J. Chromatogr. A. 1995; 705: 21–45
   PubMed Web of Science ®Google Scholar
• Gelpi E. Biomedical and biochemical applications of liquid chromatography-mass spectrometry. J. Chromatogr. A. 1995; 703: 59–80
   PubMed Web of Science ®Google Scholar
• Patterson S. D. From electrophoretically separated protein to identification: Strategies for sequence and mass analysis. Anal. Biochem. 1994; 221: 1–15
   PubMed Web of Science ®Google Scholar
• Wilm M., Shevchenko A., Houthaeve T., Breit S., Schweigerer L., Fotsis T., Mann M. Femtomole sequencing of proteins from polyacrylamide gels by nanoelectrospray mass spectrometry. Nature 1996; 379: 466–469
   PubMed Web of Science ®Google Scholar
• Toon S. The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug Metab. Pharmacokinet. 1996; 21: 93–103
   PubMed Web of Science ®Google Scholar
• Birkett D. J., Mackenzie P. I., Veronese M. E., Miners J. O. In vitro approaches can predict human drug metabolism. Trends Pharmacol. Sci. 1993; 14: 292–294
   PubMed Web of Science ®Google Scholar
• Cholerton S., Daly A. K., Idle J. R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 1992; 13: 434–439
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Muller D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 1986; 30: 287–295
   PubMed Web of Science ®Google Scholar
• Doecke C. J., Veronese M. E., Pond S. M., Miners J. O., Birkett D. J., Sansom L. N., Mc M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 1991; 31: 125–130
   PubMed Web of Science ®Google Scholar
• Buchert E., Woosley R. L. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics 1992; 2: 2–11
   PubMedGoogle Scholar
• Gross A. S., Mikus G., Fischer C., Hertrampf R., Gundert U., Eichelbaum M. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br. J. Clin. Pharmacol. 1989; 28: 555–566
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism—Clinical aspects, Pharmacol. Ther. 1990; 46: 377–394
   Google Scholar
• Butler M. A., Lang N. P., Young J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116–127
   PubMedGoogle Scholar
• Wilkinson G. R., Guengerich F. P., Branch R. A. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 1989; 43: 53–76
   PubMed Web of Science ®Google Scholar
• Aoyama T., Yamano S., Waxman D. J., Lapenson D. P., Meyer U. A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H. V. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 1989; 264: 10388–10395
   PubMed Web of Science ®Google Scholar
• Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA 1991; 88: 5237–5241
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Idle J. R. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 1994; 26: 59–70
   PubMed Web of Science ®Google Scholar
• Honkakoski P., Auriola S., Lang M. A. Distinct induction pro-files of three phenobarbital-responsive mouse liver cytochrome P450 isozymes. Biochem. Pharmacol. 1992; 43: 2121–2128
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991; 4: 391–407
   PubMed Web of Science ®Google Scholar
• Park B. K., Kitteringham N. R., Pirmohamed M., Tucker G. T. Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications. Br. J. Clin. Pharmacol 1996; 41: 477–491
   PubMed Web of Science ®Google Scholar
• Caccia S., Garattini S. Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clin. Pharmacakinet. 1990; 18: 434–459
   Google Scholar
• Caccia S., Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol. Res. 1992; 26: 317–329
   PubMed Web of Science ®Google Scholar
• Garattini S., Caccia S., Carli M., Mennini T. Notes on kinetics and metabolism of benzodiazepines. Adv. Biosci. 1981; 31: 351–364
   Google Scholar
• Garattini S., Mussini E., Randall L. O. The Benzodiazepines. Raven Press, New York 1973
   Google Scholar
• Caccia S., Muglia M., Mancinelli A., Garattini S. Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 1983; 13: 147–153
   PubMed Web of Science ®Google Scholar
• Caccia S., Fong M. H., Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)piperazine in the rat. Xenobiotica 1985; 15: 835–844
   PubMed Web of Science ®Google Scholar
• Nemeroff C. B., De C. L., Pollock B. G. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 1996; 153: 311–320
   PubMed Web of Science ®Google Scholar
• Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 1993; 71: 1002–1009
   PubMedGoogle Scholar
• Bloomer J. C., Woods F. R., Haddock R. E., Lennard M. S., Tucker G. T. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br. J. Clin. Pharmacol. 1992; 33: 521–523
   PubMed Web of Science ®Google Scholar
• van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 1993; 24: 203–220
   PubMed Web of Science ®Google Scholar
• Caccia S., Fracasso C., Garattini S., Guiso G., Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 1992; 31: 343–347
   PubMed Web of Science ®Google Scholar
• Garattini S., Bizzi A., Caccia S., Mennini T. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline. Int. J. Obes. Relat. Metab. Disord. 1992; 16(Suppl. 3)S43–S50
   PubMedGoogle Scholar
• Caccia S., Confalonieri S., Bergami A., Fracasso C., Anelli M., Garattini S. Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats. A comparison with fluoxetine. Pharmacol. Biochem. Behav, in press
   Web of Science ®Google Scholar
• Tremaine L. M., Welch W. M., Ronfeld R. A. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab. Dispos. Biol. Fate. Chem. 1989; 17: 542–550
   PubMed Web of Science ®Google Scholar
• Shah R. R. Clinical pharmacokinetics: Current requirements and future perspectives from a regulatory point of view. Xenobiotica 1993; 23: 1159–1193
   PubMed Web of Science ®Google Scholar
• Garattini S., Mennini T., Samanin R. From fenfluramine race-mate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann NY Acad. Sci. 1987; 499: 156–166
   PubMed Web of Science ®Google Scholar
• Garattini S., Mennini T., Samanin R. Advance in understanding the role of serotonin in controlling food intake. Recent Advances in Obesity Research. V. John Libbey, London 1987; 272–284
   Google Scholar
• Mennini T., Garattini S., Caccia S. Anorectic effect of fenfluramine isomers and metabolites: Relationship between brain levels and in vitro potencies on serotonergic mechanisms. Psychopharmacology (Berl.) 1985; 85: 111–114
   PubMed Web of Science ®Google Scholar
• Sedvall G., Pauli S., Farde L., Karlsson P., Nyberg S., Nordstrom A. L. Recent developments in PET scan imaging of nuroreceptors in schizophrenia. Isr. J. Psychiatry Relat. Sci. 1995; 32: 22–29
   PubMed Web of Science ®Google Scholar
• Bartels M., Albert K. Detection of psychoactive drugs using 19F MR spectroscopy. J. Neural Transm. Gen. Sect. 1995; 99: 1–6
   PubMed Web of Science ®Google Scholar
• Renshaw P. F., Guimaraes A. R., Fava M., Rosenbaum J. F., Pearlman J. D., Flood J. G., Puopolo P. R., Clancy K., Gonzalez R. G. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am. J. Psychiatry 1992; 149: 1592–1594
   PubMed Web of Science ®Google Scholar
• Karson C. N., Newton J. E., Mohanakrishnan P., Sprigg J., Komoroski R. A. Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res. 1992; 45: 95–104
   PubMed Web of Science ®Google Scholar
• Molliver D. C., Molliver M. E. Anatomic evidence for a neurotoxic effect of (+/-)-fenfluramine upon serotonergic projections in the rat. Brain Res. 1990; 511: 165–168
   PubMed Web of Science ®Google Scholar
• Mc U., Hatzidimitriou G., Ridenour A., Fischer C., Yuan J., Katz J., Ricaurte G. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther. 1994; 269: 792–798
   PubMed Web of Science ®Google Scholar
• Campbell-Brunelle B., Dard B., Caccia S. The use of pharmacokinetics in the assessment of dexfenfluramine safety. Obesity Management and Redux, S. Nicolaidis. Academic Press, San Diego 1997; 65–79
   Google Scholar
• Mennini T., Bizzi A., Caccia S., Codegoni A., Fracasso C., Frittoli E., Guiso G., Padura I. M., Taddei C., Uslenghi A., Garattini S. Comparative studies on the anorectic activity of dfenfluramine in mice, rats, and guinea pigs. Naunyn Schmiedebergs Arch. Pharmacol. 1991; 343: 483–490
   PubMed Web of Science ®Google Scholar
• Caccia S., Anelli M., Fracasso C., Frittoli E., Giorcelli P., Gobbi M., Taddei C., Garattini S., Mennini T. Anorectic effect and brain concentrations of d-fenfluramine in the marmoset: Relationship to the in vivo and in vitro effects of serotonergic mechanisms. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 347: 306–312
   PubMed Web of Science ®Google Scholar
• Latini R., Barbieri E., Castello C., Marchi S., Sica A., Gerosa G., Rossi R., Zardini P. Propafenone and 5-hydroxypropafenone concentrations in the right atrium of patients undergoing heart surgery. Am. Heart J. 1989; 117: 497–498
   PubMed Web of Science ®Google Scholar
• Philipsborn G., Gries J., Hofmann H. P. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 1984; 34: 1489–1497
   PubMed Web of Science ®Google Scholar
• Valenzuela C., Delgado C., Tamargo J. Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibres. J. Cardiovasc. Pharmacol. 1987; 10: 523–529
   PubMed Web of Science ®Google Scholar
• Zaza A., Forster M., Danilo P., Sodowick B., Rosen M. Electrophysiologic effects of propafenone and metabolites on canine Purkinje fibers. Fed. Proc. 1987; 46: 871–870
   Google Scholar
• Latini R., Maggioni A. P., Cavalli A. Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status. Clin. Pharmacokinet. 1990; 18: 91–103
   PubMed Web of Science ®Google Scholar
• Latini R., Magnolfi G., Zordan R., Ferrari M., Padrini R., Piovan D., Pecorari T., Bottazzi L., Guiducci U. Antiarrhythmic drug plasma concentrations in ambulatory patients. Ann. Pharmacother. 1996; 30: 298–300
   PubMed Web of Science ®Google Scholar
• Barbieri E., Conti F., Zampieri P., Trevi G. P., Zardini P., Latini R. Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short-and long-term treatment with amiodarone. J. Am. Coll. Cardiol. 1986; 8: 210–213
   PubMed Web of Science ®Google Scholar
• Donelli M. G., Colombo T., Dagnino G., Madonna M., Garattini S. Is better drug availability in secondary neoplasms responsible for better response to chemotherapy?. Eur. J. Cancer 1981; 17: 201–209
   PubMed Web of Science ®Google Scholar
• Donelli M. G., Garattini S. Differential accumulation of anticancer agents in metastases compared with primary tumors in experimental models. Recent Advances in Cancer Treatment, H. J. Tagnon, M. J. Staquet. Raven Press, New York 1977; 177–185
   Google Scholar
• Dincalci M. Metabolism of triazine anticancer agents. Anticancer Drugs: Reactive Metabolism and Drug Interactions, G. Powis. Pergamon Press, London 1994; 157–165
   Google Scholar
• Damia G. Clinical pharmacokinetics of altretamine. Clin. Pharmacokinet. 1995; 28: 439–448
   PubMed Web of Science ®Google Scholar
• Blum R. H., Livingston R. B., Carter S. K. Hexamethylmelamine—A new drug with activity in solid tumors. Eur. J. Cancer 1973; 9: 195–202
   PubMed Web of Science ®Google Scholar
• Legha S. S., Slavik M., Carter S. K. Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer 1976; 38: 27–35
   PubMed Web of Science ®Google Scholar
• Wharton J. T. ldquo;Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer”. Cancer Treat. Rev. 1991; 18(Suppl. A)15–21
   PubMedGoogle Scholar
• Ross D., Langdon S. P., Gescher A., Stevens M. F. Studies of the mode of action of antitumour triazenes and triazines. V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism. Biochem. Pharmacol. 1984; 33: 1131–1136
   PubMed Web of Science ®Google Scholar
• Miller K. J., Mc R. M., Ames M. M. Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. Cancer Chemother. Pharmacol. 1985; 15: 49–53
   PubMed Web of Science ®Google Scholar
• Miller-Hatch K. J., Ames M. M., Kovach J. S. Cytotoxic activity of hexamethylmelamine (HMM) in human tumor cell lines in the presence of rat hepatic preparations 1983; 247
   Google Scholar
• Collins J. M., Grieshaber C. K., Chabner B. A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 1990; 82: 1321–1326
   PubMed Web of Science ®Google Scholar
• EORTC Pharmacokinetics and Metabolism Group. Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 1987; 23: 1083–1087
   PubMedGoogle Scholar
• Graham M. A., Workman P. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies. Ann Oncol. 1992; 3: 339–347
   PubMed Web of Science ®Google Scholar
• Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat. Rev. 1982; 9: 85–124
   PubMed Web of Science ®Google Scholar
• Donelli M. G., Zucchetti M., Munzone E., Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur. J. Cancer Clin. Oncol 1996, in press
   Google Scholar
• Donelli M. G., Zucchetti M., Munzone E., Gentili D. Pharmacokinetics of anticancer agents in patients with impaird liver function. Eur. J. Cancer 1996
   Google Scholar
• Park G. R. Pharmacokinetics and pharmacodynamics in the critically ill patient. Xenobiotica 1993; 23: 1195–1230
   PubMed Web of Science ®Google Scholar
• Colombo T., Gonzalez O., Zucchetti M., Maneo M., Sessa C., Goldrhisch A. Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann. Oncol. 1996; 7: 801–805
   PubMed Web of Science ®Google Scholar
• Ford J. M., Hait W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990; 42: 155–199
   PubMed Web of Science ®Google Scholar
• Croop J. M., Raymond M., Haber D., Devault A., Arceci R. J., Gros P., Housman D. E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell Biol. 1989; 9: 1346–1350
   PubMed Web of Science ®Google Scholar
• Van P., Valk C. K.H., Broxterman H. J., Scheffer G., Kuiper C. M., Tsuruo T., Lankelma J., Meijer J. L. M., Pinedo H. M., Scheper R. J. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol. 1990; 1: 56–64
   PubMed Web of Science ®Google Scholar
• Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988; 48: 1926–1929
   PubMed Web of Science ®Google Scholar
• Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Juliano R., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976; 455
   PubMed Web of Science ®Google Scholar
• Juranka P. F., Zastawny R. L., Ling V. p-Glycoprotein: Multidrug resistance and a superfamily of membrane-associated trans-port proteins. FASEB J. 1989; 3: 2583–2592
   PubMed Web of Science ®Google Scholar
• Bitonti A. J., Sjoerdsma A., Mc P. P., Kyle D. E., Oduola A. M. J., Rossan R. N., Milhous W. K., Davidson D. E. J. Reversal of chloroquine resistance in malaria parasite plasmodium falciparum by desipramine. Science 1988; 242: 1301–1303
   PubMed Web of Science ®Google Scholar
• Dutt A., Priebe T. S., Teeter L. D., Kuo M. T., Nelson J. A. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J. Pharmacol. Exp. Then 1992; 261: 1222–1230
   PubMed Web of Science ®Google Scholar
• Dudley A. J., Brown C. D. A. Mediation of cimetidine secretion of P-glycoprotein and a novel H +-coupled mechanism in cultured renal epithelial monolayers of LLC-PK1 cells. Br. J. Pharmacol. 1996; 117: 1139–1144
   PubMed Web of Science ®Google Scholar
• Broxterman H. J., Giaccone G., Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr. Opin. Oncol. 1995; 7: 532–540
   PubMedGoogle Scholar
• Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn. J. Cancer Res. 1988; 79: 285–296
   PubMedGoogle Scholar
• Mickisch G. H., Pai L. H., Gottesman M. M., Pastan I. Mono-clonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res. 1992; 52: 4427–4432
   PubMed Web of Science ®Google Scholar
• Iwahashi T., Okochi E., Ariyoshi K., Watabe H., Amann E., Mori S., Tsuruo T., Ono K. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res. 1993; 53: 5475–5482
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41: 1967–1972
   PubMed Web of Science ®Google Scholar
• Speeg K. V. J., Mc W. L. Uptake of the noncytotoxic transport probe procainamide in the Chinese hamster ovary model of multidrug resistance. Cancer Res. 1992; 52: 3539–3546
   PubMed Web of Science ®Google Scholar
• Karlsson J., S-Kuo M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 1993; 110: 1009–1016
   PubMed Web of Science ®Google Scholar
• Phang J. M., Poore C. M., Lopaczynska J., Yeh G. C. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res. 1993; 53: 5977–5981
   PubMed Web of Science ®Google Scholar
• Chieli E., Romiti N., Cervelli F., Tongiani R. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci. 1995; 57: 1741–1751
   PubMed Web of Science ®Google Scholar
• Critchfield J. W., Welsh C. J., Phang J. M., Yeh G. C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol. 1994; 48: 1437–1445
   PubMed Web of Science ®Google Scholar
• Scambia G., Ranelletti F. O., Panici P. B., De R., Bonanno G., Ferrandina G., Piantelli M., Bussa S., Rumi C., Cianfriglia M. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 1994; 34: 459–464
   PubMed Web of Science ®Google Scholar
• Versantvoort C. H., Schuurhuis G. J., Pinedo H. M., Eekman C. A., Kuiper C. M., Lankelma J., Broxterman H. J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br. J. Cancer 1993; 68: 939–946
   PubMed Web of Science ®Google Scholar
• Sarkar M. A. Quercetin not only inhibits P-glycoprotein efflux activity but also inhibits CYP3A isozymes [letter]. Cancer Chemother. Pharmacol. 1995; 36: 448–450
   PubMed Web of Science ®Google Scholar
• Wacher V. J., Wu C. Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 1995; 13: 129–34
   PubMed Web of Science ®Google Scholar
• Gaveriaux C., Boesch D., Jachez B., Bollinger P., Payne P., Loor F. SDZ-PSC-833, a non-immunosuppressive cyclosporine analog, is a very potent multidrug-resistance modifier. J. Cell Pharmacol. 1991; 2: 225–220
   Google Scholar
• Keller R. P., Alermatt H. J., Nooter K., Poschmann G., Laissue J. A., Bollinger P., Hiestand P. C. SDZ PSC 833, a nonimmunsuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer 1992; 50: 593–597
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Bleehen N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur. J. Cancer 1991; 27: 1639–1642
   PubMed Web of Science ®Google Scholar
• Gonzalez O., Colombo T., De M., Imperatori L., Zucchetti M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol. 1995; 36: 335–340
   PubMed Web of Science ®Google Scholar
• Colombo T., Gonzalez O. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice and P388 and P388/DOX leukaemia. Br. J. Cancer 1996; 73: 866–871
   PubMed Web of Science ®Google Scholar
• Mickisch G. H., Pastan I., Gottesman M. M. Multidrug resistant transgenic mice as a novel pharmacologic tool. Bioessays 1991; 13: 381–387
   PubMed Web of Science ®Google Scholar
• Pastan I., Willingham M. C., Gottesman M. M. Molecular manipulations of the multidrug transporter: A new role for transgenic mice. FASEB J. 1991; 5: 2523–2528
   PubMed Web of Science ®Google Scholar
• Galski H., Sullivan M., Willingham M. C. Expression of a human multidrug resistance CDNA (MDR1) in the bone marrow of tansgenic mice: Resistance of daunomycin-induced leukopenia. Mol. Cell. Biol. 1989; 9: 4357
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Smit J. J. M., Wagenaar E. Efficient inactivation of the mouse mdr genes in embryonic stem cells using homologous recombination. Proc. Am. Assoc. Cancer Res. 1992; 33
   Google Scholar
• Schinkel A. H., Wagenaar E., Mol C. A., Borst P. Absence of the mdr la P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 1995; 96: 1698–1705
   PubMed Web of Science ®Google Scholar
• Uetrecht J. P. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 1992; 24: 299–366
   PubMed Web of Science ®Google Scholar
• Boyd E. M., Bereczky G. M. Liver necrosis from paracetamol. Br. J. Pharmacol. 1966; 26: 606–614
   PubMed Web of Science ®Google Scholar
• Davidson D. G., Eastham W. N. Acute liver necrosis following overdose of paracetamol. Br. Med. J. 1966; 5512: 497–499
   Web of Science ®Google Scholar
• Thomson J. S., Prescott L. F. Liver damage and impaired glucose tolerance after paracetamol overdosage. Br. Med. J. 1966; 5512: 506–507
   Google Scholar
• Raucy J. L., Lasker J. M., Lieber C. S., Black M. Acetaminophen activation by human liver cytochromes P450IIE 1 and P4501A2. Arch. Biochem. Biophys. 1989; 271: 270–283
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Pohl L. R., Monks T. J., Gillette J. R. Acetaminophen-induced hepatotoxicity. Life Sci. 1981; 29: 107–116
   PubMed Web of Science ®Google Scholar
• Snawder J. E., Roe A. L., Benson R. W., Roberts D. W. Loss of CYP2E1 and CYP1A2 activity as a function of acetaminophen dose: relation to toxicity. Biochem. Biophys. Res. Commun. 1994; 203: 532–539
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Pumford N. R., Roberts D. W. Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab. Rev. 1995; 27: 73–92
   PubMed Web of Science ®Google Scholar
• Pumford N. R., Martin B. M., Hinson J. A. A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem. Biophys. Res. Commun. 1992; 182: 1348–1355
   PubMed Web of Science ®Google Scholar
• Cook R. J., Lloyd R. S., Wagner C. Isolation and characterization of cDNA clones for rat liver 10-formyltetrahydrofolate dehydrogenase. J. Biol. Chem. 1991; 266: 4965–4973
   PubMed Web of Science ®Google Scholar
• Myers T. G., Dietz E. C., Anderson N. L., Khairallah E. A., Cohen S. D., Nelson S. D. A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3′-hydroxyacetanilide. Chem. Res. Toxicol. 1995; 8: 403–413
   PubMed Web of Science ®Google Scholar
• Tirmenstein M. A., Nelson S. D. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J. Biol. Chem. 1989; 264: 9814–9819
   PubMed Web of Science ®Google Scholar
• Moore M., Thor H., Moore G., Nelson S., Moldeus P., Orrenius S. The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+. J. Biol. Chem. 1985; 260: 13035–13040
   PubMed Web of Science ®Google Scholar
• Tsokos J. O., Todd E. L., Mc J. B., Mitchell J. R. ATP-dependent calcium uptake by rat liver plasma membrane vesicles. Effect of alkylating hepatotoxins in vivo. Mol. Pharmacol. 1985; 28: 56–61
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Seddon C. E., Nasseri P., Davies D. S. Evidence for a direct role of intracellular calcium in paracetamol toxicity. Biochem. Pharmacol. 1990; 39: 1277–1281
   PubMed Web of Science ®Google Scholar
• Nicotera P., Rundgren M., Porubek D. J., Cotgreave I., Moldeus P., Orrenius S., Nelson S. D. On the role of Ca2+ in the toxicity of alkylating and oxidizing quinone imines in isolated hepatocytes. Chem. Res. Toxicol. 1989; 2: 46–50
   PubMed Web of Science ®Google Scholar
• Ray S. D., Sorge C. L., Raucy J. L., Corcoran G. B. Early loss of large genomic DNA in vivo with accumulation of Ca2+ in the nucleus during acetaminophen-induced liver injury. Toxicol. Appl. Pharmacol. 1990; 106: 346–351
   PubMed Web of Science ®Google Scholar
• Shen W., Kamendulis L. M., Ray S. D., Corcoran G. B. Acetaminophen-induced cytotoxicity in cultured mouse hepatocytes: Effects of Ca(2+)-endonuclease, DNA repair, and glutathione depletion inhibitors on DNA fragmentation and cell death. Toxicol. Appl. Pharmacol. 1992; 112: 32–40
   PubMed Web of Science ®Google Scholar
• Ray S. D., Kamendulis L. M., Gurule M. W., Yorkin R. D., Corcoran G. B. CA2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB, J. 1993; 7: 453–463
   PubMed Web of Science ®Google Scholar
• Alvir J. M., Lieberman J. A. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience [editorial]. J. Clin. Psychopharmacol. 1994; 14: 87–89
   PubMed Web of Science ®Google Scholar
• Maggs J. L., Williams D., Pirmohamed M., Park B. K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 1995; 275: 1463–1475
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Update of hepatotoxicity due to classes of drugs in common clinical use: non steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin. Liver Dis. 1990; 10: 322–338
   PubMed Web of Science ®Google Scholar
• Dunk A. A., Walt R. P., Jenkins W. J., Sherlock S. S. Diclofenac hepatitis. Br. Med. J. Clin. Res. Ed. 1982; 284: 1605–1606
   PubMed Web of Science ®Google Scholar
• Helfgott S. M., Sandberg J., Zakim D., Nestler J. Diclofenac-associated hepatotoxicity [see comments]. JAMA 1990; 264: 2660–2662
   PubMed Web of Science ®Google Scholar
• Purcell P., Henry D., Melville G. Diclofenac hepatitis. Gut 1991; 32: 1381–1385
   PubMed Web of Science ®Google Scholar
• Breen E. G., Mc J., Cosgrove E., Mc J., Stevens F. M. Fatal hepatitis associated with diclofenac. Gut 1986; 27: 1390–1393
   PubMed Web of Science ®Google Scholar
• Faed E. M. Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 1984; 15: 1213–1249
   PubMed Web of Science ®Google Scholar
• Olson J. A., Moon R. C., Anders M. W., Fenselau C., Shane B. Enhancement of biological activity by conjugation reactions. J. Nutr. 1992; 122: 615–624
   PubMed Web of Science ®Google Scholar
• Spahr H., Benet L. Z. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism?. Drug Metab. Rev. 1992; 24: 5–47
   PubMed Web of Science ®Google Scholar
• Kenna J. G. The molecular basis of halothane-induced hepatitis. Biochem. Soc. Trans. 1991; 19: 191–195
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Martin J. L., Satoh H., Pohl L. R. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Dispos. 1990; 18: 788–793
   PubMed Web of Science ®Google Scholar
• Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315–317
   PubMed Web of Science ®Google Scholar
• Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistarderived rats. Cancer Res. 1993; 53: 3919–3924
   PubMed Web of Science ®Google Scholar
• Seoud M. A., Johnson J., Weed J. C. J. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol. 1993; 82: 165–169
   PubMed Web of Science ®Google Scholar
• Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M. Endometrial cancer in tamoxifentreated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [Prior annotation incorrect] [see comments]. J. Natl. Cancer Inst. 1994; 86: 527–537
   PubMed Web of Science ®Google Scholar
• Han X., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992; 52: 1360–1363
   PubMed Web of Science ®Google Scholar
• White I. N., De F., Davies A., Smith L. L., Crofton C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/ 2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992; 13: 2197–2203
   PubMed Web of Science ®Google Scholar
• Carthew P., Rich K. J., Martin E. A., De F., Lim C. K., Manson M. M., Festing M. F., White I. N., Smith L. L. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis 1995; 16: 1299–1304
   PubMed Web of Science ®Google Scholar
• Pathak D. N., Bodell W. J. DNA adduct formation by tamoxifen with rt and human liver microsomal activation systems. Carcinogenesis 1994; 15: 529–532
   PubMed Web of Science ®Google Scholar
• Pathak D. N., Pongracz K., Bodell W. J. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 1995; 16: 11–15
   PubMed Web of Science ®Google Scholar
• Phillips D. H., Carmichael P. L., Hewer A., Cole K. J., Hardcastle I. R., Poon G. K., Keogh A., Strain A. J. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996; 17: 89–94
   PubMed Web of Science ®Google Scholar
• Moorthy B., Sriram P., Pathak D. N., Bodell W. J., Randerath K. Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 1996; 56: 53–57
   PubMed Web of Science ®Google Scholar
• Phillips D. H., Carmichael P. L., Hewer A., Cole K. J., Poon G. K. Alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 1994; 54: 5518–5522
   PubMed Web of Science ®Google Scholar
• Randerath K., Moorthy B., Mabon N., Sriram P. Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 1994; 15: 2087–2094
   PubMed Web of Science ®Google Scholar
• Potter G. A., Mc Cague R., Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 1994; 15: 439–442
   PubMed Web of Science ®Google Scholar
• Osborne M. R., Hewer A., Hardcastle I. R., Carmichael P. L., Phillips D. H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 1996; 56: 66–71
   PubMed Web of Science ®Google Scholar
• Caccia S., Garattini S. Pharmacological implications of drug metabolism. The Physiology of Xenobiotic Metabolism. Wiley, New York 1996, in press
   Google Scholar
• Caccia S., Garattini S. Benzodiazepines. Handbook of Experimental Pharmacology, H. H. Frey, D. Janz. Springer Verlag, Berlin 1985; 575–593
   Google Scholar
• Wong D. T., Fuller R. W. Serotonergic mechanisms in feeding. Int. J. Obes. 1987; 11(suppl. 3)125–133
   PubMedGoogle Scholar
• Anelli M., Bizzi A., Caccia S., Codegoni A. M., Fracasso C., Garattini S. Anoerectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs. J. Pharm. Pharmacol. 1992; 44: 696–698
   PubMed Web of Science ®Google Scholar
• Gobbi M., Frittoli E., Mennini T., Garattini S. Releasing activities of d-fenfluramine and fluoxetine on hippocampal synaptosomes preloaded with (3H)serotonin. Naunyn Schmiedebergs Arch. Pharmacol. 1992; 345: 1–6
   PubMed Web of Science ®Google Scholar
• Borroni E., Ceci A., Garattini S., Mennini T. Differences between d-fenfluramine and d-norfenfluramine in serotonin presynaptic mechanisms. J. Neurochem. 1983; 40: 891–893
   PubMed Web of Science ®Google Scholar
• Mennini T., Gobbi M., Crespi D., Cinquanta M., Frittoli E., Giorcell P., Anelli M., Caccia S. In vivo and in vitro interaction of flunarizine with d-fenfluramine serotonergic effects. Pharmacol. Biochem. Behav. 1996; 53: 155
   PubMed Web of Science ®Google Scholar
• Gibson E. L., Kennedy A. J., Curzon G. Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur. J. Pharmacol. 1993; 242: 83–90
   PubMed Web of Science ®Google Scholar
• Conn P. J., Sanders E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-lc) receptors. J. Pharmacol. Exp. Pier. 1987; 242: 552–557
   PubMed Web of Science ®Google Scholar
• Samanin R., Mennini T., Ferraris A., Bendotti C., Borsini F., Garattini S. m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch. Pharmacol. 1979; 308: 159–163
   PubMed Web of Science ®Google Scholar
• Bianchi G., Caccia S. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)-piperazine in rat plasma and brain by high-performance liquid chromatography. J. Chromatogr. 1988; 431: 477–480
   PubMed Web of Science ®Google Scholar
• Gobbi M., Frittoli E., Mennini T. Antagonist properties of 1-(2-pyrimidinyl)piperazine at presynaptic alpha2-adrenoceptors in the rat brain. Eur. J. Pharmacol. 1990; 180: 183–186
   PubMed Web of Science ®Google Scholar
• Raiteri M., Maura G., Versace P. nctional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. Pharmacol. Exp. Ther. 1983; 224: 679–684
   PubMed Web of Science ®Google Scholar
• Bianchi G., Caccia S., Della F., Garattini S. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur. J. Pharmacol. 1988; 151: 365–371
   PubMed Web of Science ®Google Scholar
• Bonanno P., Fassio A., Severi P., Ruelle A., Raiteri M. Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism. J. Neurochem. 1994; 63: 1163–1166
   PubMed Web of Science ®Google Scholar